Pulmonary Arterial Hypertension (PAH) Medicine Market

Pulmonary arterial hypertension is a condition in which the blood pressure in the arteries that supply blood to the lungs becomes too high. This can cause shortness of breath, chest pain, and other symptoms. If left untreated, PAH can lead to heart failure and death. There are several medicines available to treat PAH, including sitaxentan, ambrisentan, bosentan, treprostinil, and sildenafil. These drugs are used in combination with other treatments, such as oxygen therapy and lifestyle changes. The rising prevalence of PAH is the major factor driving the growth of the market. According to the World Health Organization (WHO), the prevalence of PAH was about 15-16 cases per million people in 2015. The WHO also estimates that there are currently between 20-30 million people living with PAH worldwide. Other factors driving market growth include the availability of new and effective treatments, the increasing number of clinical trials for PAH, and the growing number of patients being diagnosed with the condition.

Pulmonary Arterial Hypertension (PAH) Medicine Market Driving Factors

This growth is attributed to the high incidence of PAH, increasing awareness about the disease, and the availability of approved therapies. PAH is a rare but progressive and life-threatening disorder that affects small arteries in the lungs and raises blood pressure in these vessels. The symptoms include shortness of breath, fatigue, chest pain, fainting, and swollen ankles or legs. PAH can lead to right heart failure and death if left untreated.

There are several approved therapies available for PAH, which are effective in reducing symptoms and improving exercise capacity. These include prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and soluble guanylate cyclase stimulators. Prostacyclin analogs are the most commonly used drugs for PAH; however, they are associated with several side effects such as nausea, vomiting, diarrhea, headache, flushing, and dizziness.

The other driving factors for the PAH medicine market include the launch of new therapies such as selexipag and macitentan; growing preference for targeted therapies; and increasing R&D investments by key players. However, the high cost of treatment and lack of awareness about PAH among healthcare professionals are restraining the growth of this market to some extent.

Covid-19 Impact Analysis

Covid-19 has had a significant impact on the pulmonary arterial hypertension (PAH) medicine market. The pandemic has resulted in a decrease in the demand for PAH medicines and a decrease in the prices of these medicines. This is because many patients with PAH are unable to receive treatment due to the closure of hospitals and clinics. In addition, the pandemic has also resulted in a shortage of PAH medicines, as many manufacturers have been forced to shut down their production facilities.

The global pulmonary arterial hypertension (pah) medicine market outlook study is a comprehensive databook that provides key market data on the global pulmonary arterial hypertension (pah) medicine industry. Some of the prominent players in the market are Actelion Pharmaceuticals, Eli Lilly, Gilead Sciences, Pfizer, United Therapeutics Corporation. The research report on the global pulmonary arterial hypertension (pah) medicine market provides extensive competition analysis and competitive conditions. The report includes information on significant products, players, challenges and developments, and other information specific to the market.

Goals and Objectives of the Global Pulmonary Arterial Hypertension (PAH) Medicine Market Study

The purpose of this study is to identify the current market environment for pulmonary arterial hypertension (pah) medicine and to assess the market's potential for growth over the forecast period. The research delves into market factors affecting the pulmonary arterial hypertension (pah) medicine market (drivers, restraints, opportunities, and trends). The current market for pulmonary arterial hypertension (pah) medicine is examined in this report, as well as the market's future trajectory.

• The reasons for doing this study are to:
  • To generate a detailed industry structure, provide a comprehensive analysis of the pulmonary arterial hypertension (pah) medicine market industry and its segments in the global market.
  • Provide detailed insights into the factors driving and restraining the global market for pulmonary arterial hypertension (pah) medicine growth.
  • Estimate the size of the global market for pulmonary arterial hypertension (pah) medicine.
  • Examine the global market for pulmonary arterial hypertension (pah) medicine in terms of key countries and regions.
  • Provide country-level market value analysis for key segments of the pulmonary arterial hypertension (pah) medicine market.
  • Provide strategic profiling of key global companies, as well as a thorough analysis of their competitiveness and the overall competitive landscape in this market.

The second chapter, market overview, provides an overview of the pulmonary arterial hypertension (pah) medicine market. The chapter discusses macroeconomic factors, drivers, restraints, opportunities, challenges, value chain analysis, technology roadmap, and Porter 5 force model analysis.

Scope of the Report

The global pulmonary arterial hypertension (pah) medicine market is extensive, with a detailed description and evaluation of the market. It includes extensive qualitative and quantitative insights into the report that are aligned with our intended customers' goals and objectives.

Global Pulmonary Arterial Hypertension (PAH) Medicine Market Segmentation

Chapter 3, segment analysis provides information on the different sub-segments of the market. The chapter provides an in-depth analysis of the market segments and year-on-year growth projections that enable readers to identify potential market growth areas.

• Based on product type, the global pulmonary arterial hypertension (pah) medicine market is segmented into calcium channel blockers, novel targeted drugs, other.
• Based on application, the pulmonary arterial hypertension (pah) medicine market is segmented into secondary pulmonary hypertension (sph), primary pulmonary hypertension (pph).

Global Pulmonary Arterial Hypertension (PAH) Medicine Market Regional Analysis

Chapter 4, the regional analysis includes an in-depth analysis of the pulmonary arterial hypertension (pah) medicine market by region. The chapter covers several regions, including North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The report also includes a comprehensive analysis of the market by country. The report covers countries such as the United States, Canada, Germany, France, Italy, Spain, China, India, Japan, the GCC, South Africa, Brazil, Mexico, and the rest of the world. Regional insight helps market competitors to make crucial decisions about their company. Individualized, country-wise, and segment-wise analyses by region allow readers to explore the potential of the market in different geographies. This section is a vital part of the report for each year’s growth projections and a global share of value.

Global Pulmonary Arterial Hypertension (PAH) Medicine Market Competitive Analysis

Chapter 5, a competitive analysis of the report includes company shares analysis, a list of acquisitions, mergers, collaboration, and the introduction of new products.

Global Pulmonary Arterial Hypertension (PAH) Medicine Market Company Profile

Chapter 6, the company profile of the report also covers key industry players working in the pulmonary arterial hypertension (pah) medicine market. The report also discusses the business strategies adopted by the players at the global, regional, and country-level. The study also focuses on various businesses or inorganic business development strategies for expanding consumer networks through product formation, organization extension, partnerships, mergers, and acquisitions.

Sources of Information

• Primary Research: Email correspondence and phone interviews are two common methods of conducting primary research. Primary interviews aid in the validation of data and information, the development of secondary sources, and the collection of data for market nodes where secondary sources are unavailable. Participants in this type of process typically include:
  • CEOs, VPs, marketing/product managers, market intelligence managers, and national sales managers are among the industry participants.
  • External experts include investment bankers, valuation specialists, and research analysts who specialize in specific medical equipment markets.

• Secondary Research: The research process entails conducting extensive secondary research on internal and external sources to gather qualitative and quantitative market information. The first step in the secondary research is to prepare a list of companies and product mapping for market nodes. The next step is to collect data and information from the public domain for the market nodes. The following are examples of secondary research sources:
  • Financial reports, broker reports, investor presentations, and SEC filings.
  • Journals of industry, scientific journals, and other technical literature
  • Patent and regulatory databases that are relevant.
  • Documents from the national government and statistical databases
  • News articles, press releases, and webcasts specific to market participants.